
PVP closes €3m series-A for CryoTherapeutics
Peppermint Venture Partners (PVP) has joined an investor consortium including High-Tech Gründerfonds (HTGF) in a €3m series-A round for German biotech company CryoTherapeutics.
PVP's investment closed the €3m round for CryoTherapeutics, which received capital from HTGF, NRW Bank and private investors in June 2012. The company will use the funding to enter its product into the clinical development stage and move its office to Cologne.
Company
CryoTherapeutics was established in December 2009 by a team of serial entrepreneurs from the UK, US and Canada.
The company focuses on developing a catheter system, which utilises cryoenergy to treat and prevent heart attacks. The initial objective of the company is to demonstrate the clinical benefits of the treatment to heart attack patients. The system is to be used by interventional cardiologists.
People
Joachim Rautter is managing partner at PVP, while Kay Balster is investment manager at HTGF.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater